Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer

To test whether two sequential BCG-induction courses improves the response of high-risk non-muscle invasive bladder cancer. Achieving a complete response (CR) to BCG is critical to disease-free survival. Patients with preexisting BCG-specific immunity owing to prior exposure to BCG have longer disease-free survival than BCG-na ïve patients likely due to heterologous immunity from the initial priming of the immune system. We evaluated this hypothesis in a phase II prospective clinical trial.

Source: Urology - July 15, 2021 Category: Urology & Nephrology Authors: Harry Herr, Emily A. Vertosick, Guido Dalbagni, Eugene K Cha, Robert Smith, Nicole Benfante, Daniel D. Sjoberg, John P Sfakianos Source Type: research